Future Developments

Near-Term Focus:

EPM301 for Individuals with Prader-Willi syndrome (PWS)

Our immediate priority is advancing EPM301 through clinical development to discover its safety and efficacy in treating hyperphagia, anxiety/behavior, and improve the sleep/wake cycle in PWS patients —all critical needs with few approved therapies.

Learn more about the science behind the breakthroughs:

Future Developments:

Expanding the therapeutic impact of EPM301 and our other patented CBDA molecules

1 Genetic & Acquired Obesity Syndromes ($37.1B Market by 2031)

A future development potential is for EPM301's utility in general population weight loss and weight management as well as for Genetic Obesity Syndromes.

2 Anxiety, Sleep Disorders, & Psychiatric Disorders ($16.1B Market by 2032)

284 million patients worldwide

North America accounts for the largest market share of treatments accounting for over 45%.

3 Other Therapeutic Applications

EPM301 is just one of 14 unique molecules epm Therapeutics holds in our I.P. stable with identified potential therapeutic value in:

Dermatology
Gastro-Intestinal
General Inflammatory Conditions